Research Analysts Offer Predictions for Oramed Pharmaceuticals Inc.’s Q1 2025 Earnings (NASDAQ:ORMP)

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Oramed Pharmaceuticals in a research report issued to clients and investors on Monday, May 20th. HC Wainwright analyst R. Selvaraju expects that the biotechnology company will earn ($0.07) per share for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Oramed Pharmaceuticals’ current full-year earnings is ($0.26) per share. HC Wainwright also issued estimates for Oramed Pharmaceuticals’ Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.36) EPS.

Oramed Pharmaceuticals (NASDAQ:ORMP) last released its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.04.

Oramed Pharmaceuticals Stock Performance

Shares of NASDAQ:ORMP opened at $2.30 on Tuesday. Oramed Pharmaceuticals has a 52-week low of $1.67 and a 52-week high of $4.93. The firm has a market capitalization of $93.45 million, a P/E ratio of 8.85 and a beta of 1.87. The stock has a 50 day moving average price of $2.54 and a 200-day moving average price of $2.52.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ORMP. BML Capital Management LLC raised its position in shares of Oramed Pharmaceuticals by 61.5% in the 4th quarter. BML Capital Management LLC now owns 1,261,559 shares of the biotechnology company’s stock worth $2,914,000 after acquiring an additional 480,267 shares in the last quarter. Murchinson Ltd. grew its stake in shares of Oramed Pharmaceuticals by 31.4% in the 1st quarter. Murchinson Ltd. now owns 1,379,495 shares of the biotechnology company’s stock worth $4,028,000 after buying an additional 329,495 shares during the last quarter. Rathbones Group PLC purchased a new stake in shares of Oramed Pharmaceuticals in the 3rd quarter worth approximately $756,000. Virtu Financial LLC purchased a new stake in shares of Oramed Pharmaceuticals in the 1st quarter worth approximately $68,000. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of Oramed Pharmaceuticals in the 1st quarter worth approximately $54,000. Institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.